Using the BRAF inhibitor dabrafenib, the MEK inhibitor trametinib and the chemotherapeutic agent cisplatin, we first derived a panel of melanoma cell lines that respectively developed resistance to these three therapeutics (Supplementary Fig. 4c, d). This evidence concerns the gene MAP2K7 and melanoma.